Seattle Children's spins out BrainChild Bio, a startup developing therapies for incurable brain cancers – GeekWire geekwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from geekwire.com Daily Mail and Mail on Sunday newspapers.
Seattle Children's launches BrainChild Bio to accelerate CAR T-cell therapies for children with brain tumors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Affinivax is developing a vaccine to combat pneumococcal diseases which include pneumonia and meningitis as well as milder illnesses such as sinusitis.
GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones .